The use of digital health technology (DHT) is increasing worldwide. Clinical trials assessing available health tools for the ...

AbbVie Inc. took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, tax reform is the key to boosting U.S. manufacturing. The ...

Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune ...

An AbbVie research and development lab in San Francisco. (Brian L. Frank for The Wall Street Journal) Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other ...

For its first quarter of this year, AbbVie's net revenue was $13.3 billion, representing a sturdy 8% improvement on a year-over-year basis. Much of this was due to a nearly 17% rise in sales of ...

It beat convincingly on both the top and bottom lines. For its first quarter of this year, AbbVie's net revenue was $13.3 billion, representing a sturdy 8% improvement on a year-over-year basis.

Rob Stothard / Bloomberg via Getty Images AbbVie's first-quarter sales and adjusted earnings per share topped estimates. The drugmaker lifted its full-year adjusted EPS forecast by 10 cents.

AbbVie's first-quarter results improved with revenue growth powered by soaring sales for treatments in its immunology portfolio, prompting the company to raise its outlook for the year even as ...

AbbVie aims to invest $10 billion in the U.S. through 2035 to support its current growth plans and expand into new areas like obesity, the Chicago drugmaker’s CEO, Rob Michael, said on a call ...

AbbVie Inc. raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments, but warned its forecast doesn’t take into account any potential changes in ...

AbbVie's Q1 EPS of $2.46 beat estimates; sales rose 8.4% to $13.34 billion, topping consensus of $12.92 billion. Skyrizi and Rinvoq sales surged 70.5% and 57.2%, while Humira dropped 50.6%. Don ...

AbbVie (ABBV) reported its first-quarter 2025 earnings, surpassing Wall Street expectations with an adjusted EPS of $2.46, compared to the forecasted $2.39. The company also reported revenues of $ ...